Skip to content
StockMarketAgent

AVGO vs QCOM: side-by-side analysis

Cross-read of AVGO (Broadcom Inc.) versus QCOM (QUALCOMM Incorporated): AVGO looks meaningfully overvalued at $413 versus a fair-value midpoint of $203, while QCOM appears in our peer table. Our current rating for AVGO is Sell.

Where AVGO and QCOM sit on fair value

AVGO's composite fair-value range is $147–$261 (midpoint $203), versus a current price of $413. QCOM is one of AVGO's closest sector neighbours and shows up directly in the peer table inside our full report. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.

Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between AVGO and QCOM is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.

Where they actually differ

AVGO is classified as a mature compounder stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. QCOM, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 22.8× forward P/E with a PEG of 1.14 is not the same on AVGO as it is on QCOM unless they share the same growth profile, capital intensity, and moat half-life.

AVGO's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against QCOM should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.

Which one wins on each dimension

Valuation: AVGO looks meaningfully overvalued versus our fair-value midpoint. The full report's peer table compares AVGO and QCOM directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for AVGO is bound by the kill-scenarios list in Section 2; the equivalent for QCOM would need its own report. We do not co-rate two companies on a single page.

Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether AVGO or QCOM is the better expression of the same theme.

Bottom line — AVGO or QCOM?

Our rating for AVGO is Sell with a 88/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes QCOM. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.

For the full evidence on AVGO, including the explicit peer multiples versus QCOM and the rest of the comp set, see the canonical report at /stocks/avgo/analysis. For QCOM's standalone report, see /stocks/qcom/analysis.

Frequently asked questions

AVGO vs QCOM: which is cheaper today?

AVGO looks meaningfully overvalued at $413 versus a fair-value midpoint of $203 (range $147–$261). The peer table inside the full report compares AVGO and QCOM directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.

Is AVGO a better buy than QCOM?

Our current rating for AVGO is Sell; we do not co-rate QCOM on this page — see QCOM's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.

What archetype is AVGO?

Broadcom Inc. is classified as a mature compounder stock, which determines our deceleration curve, terminal multiple, and probability weights. QCOM's own archetype is in its own report.

What is AVGO's moat score versus QCOM?

AVGO's moat score is 9/10. The full moat section covers source, durability, and threat timeline; QCOM's moat assessment is in its own standalone report.

Research for educational purposes. Not personalised investment advice. See the full AVGO report for the canonical evidence.